Cribstone Capital Management LLC boosted its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 8.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 625 shares of the medical research company’s stock after buying an additional 50 shares during the period. Cribstone Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $109,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in TMO. Proficio Capital Partners LLC increased its stake in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after buying an additional 253 shares in the last quarter. Independent Portfolio Consultants Inc. increased its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares in the last quarter. Sharkey Howes & Javer increased its stake in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares in the last quarter. CWM LLC increased its stake in Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock worth $124,000 after buying an additional 103 shares in the last quarter. Finally, FNY Managed Accounts LLC purchased a new stake in Thermo Fisher Scientific during the first quarter worth about $153,000. Institutional investors and hedge funds own 87.60% of the company’s stock.
Thermo Fisher Scientific Inc (NYSE:TMO) traded down 0.19% on Friday, reaching $172.57. The company had a trading volume of 1,182,702 shares. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The stock’s 50 day moving average is $176.71 and its 200-day moving average is $166.56. The stock has a market capitalization of $67.32 billion, a P/E ratio of 30.06 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the firm posted $2.03 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.45%.
ILLEGAL ACTIVITY WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/19/cribstone-capital-management-llc-boosts-position-in-thermo-fisher-scientific-inc-tmo-updated-updated-updated.html.
A number of equities research analysts have issued reports on TMO shares. Deutsche Bank AG boosted their price target on Thermo Fisher Scientific from $163.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, April 28th. BTIG Research boosted their price target on Thermo Fisher Scientific from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Barclays PLC set a $175.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 26th. Leerink Swann set a $187.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, April 27th. Finally, Bank of America Corporation lifted their price objective on Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, May 9th. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $188.56.
In other Thermo Fisher Scientific news, insider Daniel P. Shine sold 4,688 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total transaction of $805,773.44. Following the completion of the sale, the insider now directly owns 29,200 shares of the company’s stock, valued at approximately $5,018,896. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jim P. Manzi sold 11,318 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the sale, the director now directly owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Insiders have sold a total of 39,506 shares of company stock valued at $6,834,758 over the last ninety days. 0.49% of the stock is owned by company insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.